Nasty aftertaste like grapefruit; This spontaneous case was reported by a patient and describes the occurrence of DYSGEUSIA (Nasty aftertaste like grapefruit) in a 69-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 002m21a, 012h21b, 019b21a and 022m20a) for COVID-19 vaccination.    Co-suspect product included non-company product NIRMATRELVIR, RITONAVIR (PAXLOVID) for COVID-19 treatment.    The patient's past medical history included Stroke. Concurrent medical conditions included Diabetic, Hypertension and Penicillin allergy. Concomitant products included LOSARTAN from December 2010 to May 2022, METOPROLOL from April 2013 to 22-May-2022, METOPROLOL from 15-Jun-2021 to 22-May-2022, HYDRALAZINE from May 2021 to 22-May-2022, ASPIRIN [ACETYLSALICYLIC ACID] from April 2013 to 22-May-2022, AMLODIPINE from April 2013 to 22-May-2022 and ROSUVASTATIN from June 2021 to 22-May-2022 for an unknown indication.   On 04-Mar-2021 at 10:00 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Apr-2021 at 1:00 PM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 18-Dec-2021 at 10:00 AM, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 23-Apr-2022 at 1:30 PM, received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 16-May-2022, the patient started NIRMATRELVIR, RITONAVIR (PAXLOVID) (unknown route) at an unspecified dose. On 19-May-2022,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced DYSGEUSIA (Nasty aftertaste like grapefruit). At the time of the report, DYSGEUSIA (Nasty aftertaste like grapefruit) had not resolved.            The patient's date of birth was reported as ??-DEC-1952.  The patient was having other medications within 2 weeks of starting COVID-19 treatment.  Company Comment: This regulatory authority case concerns a 69 year old male patient with relevant concurrent medical history of hypertension , Diabetes, and previous Stroke , who experienced Non-serious , unexpected , event of Dysguesia  which occurred on an unknown date post vaccination with the 4th dose of mRNA-1273 vaccine. The Dose 1-3 of Covid 19 vaccine of this patient was reported to be mRNA-1273 vaccine as well. It was reported that patient received a Co-suspect product, non-company product NIRMATRELVIR, RITONAVIR (PAXLOVID) for COVID-19 treatment. given at an unspecified dose and frequency for 3 days. The details surrounding the event was not reported including other treatment information , results of laboratories /diagnostic procedures like Covid 19 tests. There was no mention if any medical consult was done. Outcome of the event was reported as not resolved.  The benefit -risk relationship of mRNA -1273 ( Moderna Covid 19 Vaccine) is not affected by this report.; Sender's Comments: This regulatory authority case concerns a 69 year old male patient with relevant concurrent medical history of hypertension , Diabetes, and previous Stroke , who experienced Non-serious , unexpected , event of Dysguesia  which occurred on an unknown date post vaccination with the 4th dose of mRNA-1273 vaccine. The Dose 1-3 of Covid 19 vaccine of this patient was reported to be mRNA-1273 vaccine as well. It was reported that patient received a Co-suspect product, non-company product NIRMATRELVIR, RITONAVIR (PAXLOVID) for COVID-19 treatment. given at an unspecified dose and frequency for 3 days. The details surrounding the event was not reported including other treatment information , results of laboratories /diagnostic procedures like Covid 19 tests. There was no mention if any medical consult was done. Outcome of the event was reported as not resolved.  The benefit -risk relationship of mRNA -1273 ( Moderna Covid 19 Vaccine) is not affected by this report.